Eli Lil­ly gets a short cut at FDA for abe­maci­clib; Ca­lyxt files for $100M IPO

⇨ Look­ing to play catch-up with the lead­ers in the CDK 4/6 can­cer field, Eli Lil­ly scored the in­side track at the FDA for abe­maci­clib, now un­der re­view for breast can­cer. The agency is giv­ing the drug a pri­or­i­ty re­view, shav­ing four months off the agency’s re­view sched­ule. “We are pleased that the FDA has grant­ed abe­maci­clib Pri­or­i­ty Re­view, both as a po­ten­tial monother­a­py and com­bi­na­tion ther­a­py [with ful­ves­trant] for pa­tients with ad­vanced breast can­cer,” said Levi Gar­raway, se­nior vice pres­i­dent, glob­al de­vel­op­ment and med­ical af­fairs, Lil­ly On­col­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.